1stOncology™: Cancer Intelligence Service – Page 6172 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

On July 08, 2022 GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, reported the half-year report of the liquidity contract with Crédit Industriel et Commercial (Press release, Genfit, JUL 8, 2022, https://ir.genfit.com/news-releases/news-release-details/genfit-half-year-report-liquidity-contract-credit-industriel-4 [SID1234616560]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2022:

160,021 shares
€449,526.73
During the first half of 2022, total trading was:

On the buy side: 584,445 shares for a total amount of €2,076,404.94
On the sell side: 561,436 shares for a total amount of €2,013,057.81
During this same period, the number of trades were:

On the buy side: 2,452
On the sell side: 2,289
As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

27, 911 shares
€769 849,43

CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION

On July 8, 2022 CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, reported that Precision Autoimmune Therapeutics Co., Ltd., (PAT), previously known as Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd (TIANSHI), has completed the first-round financing which raised RMB140 million (approximately $21 million) (Press release, CASI Pharmaceuticals, JUL 8, 2022, View Source [SID1234616559]). After completion of the first-round financing, CASI holds a 15% stake in PAT.

On May 25, 2022, CASI and PAT entered into a worldwide sub-license agreement for the investigational anti-CD38 monoclonal antibody, CID-103, for the treatment, prevention, and diagnosis of autoimmune diseases, conditions, and disorders in humans. Under the terms of the agreement, CASI maintains exclusive US commercialization and co-marketing rights of CID-103 in autoimmune indications in the United States. CASI also has the co-commercial rights in the autoimmune-derived hematology indications for CID-103 in China, but is not obligated to co-commercialize those programs. Upon the completion of PAT’s first-round of financing, PAT will pay CASI US $5 million equivalent as the first part of two-installments upfront payment under the license agreement.

Wei-Wu He, Ph.D., CASI’s Chairman and Chief Executive Officer, said "The successful completion of PAT’s first-round financing allows PAT to move forward with the CID-103 autoimmune development program. By partnering with PAT, the development of CID-103 in the autoimmune indications will proceed external to CASI’s budget during a period of challenging biotech funding. Partnership with PAT will accelerate the development and potential commercialization of CID-103 in autoimmune disease, autoimmune-derived hematology indications, both are mutually beneficial to the PAT and CASI shareholders."

Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

On July 8, 2022 Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, reported that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand beginning Monday, July 11, 2022 (Press release, Aileron Therapeutics, JUL 8, 2022, View Source [SID1234616558]). Management will be available for in-person meetings at the conference on Tuesday, July 12, 2022.

A webcast of the fireside chat will be available under the Investors and Media section of Aileron’s website at View Source A replay of the webcast will be archived on Aileron’s website for 30 days following the event.

AbbVie to Host Second-Quarter 2022 Earnings Conference Call

On July 8, 2022 AbbVie (NYSE: ABBV) reported that it will announce its second-quarter 2022 financial results on Friday, July 29, 2022, before the market opens (Press release, AbbVie, JUL 8, 2022, View Source [SID1234616557]). AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Antti Vuolanto appointed as CEO of Herantis as of 22 July 2022

On July 8, 2022 Herantis Pharma Plc reported that has appointed Antti Vuolanto (born 1975) as CEO as of 22July2022 (Press release, Herantis Pharma, JUL 8, 2022, View Source,c3598918 [SID1234616555]). Frans Wuite will continue as interim CEO of Herantis Pharma Plc until 21July2022 and as Member of the Board also thereafter.

Antti Vuolanto has acted as the Chief Operating Officer of Herantis Pharma Plc since 2018. Vuolanto graduated as Doctor of Science in Technology at Aalto University, Finland in 2004 in biochemistry and bioprocess technology. He has vast experience in biological drug development, gene therapy products, in-vitro diagnostics, and bioinformatics.

"The Board of Directors commenced the CEO recruitment process in January this year. I am very pleased that, after careful evaluation, we found an internal successor within the company who is well equipped to take over the role of CEO. As a result of his management position in the company, Antti Vuolanto has strong experience and knowledge of Herantis’ business and strategic development, as well as due to his background, expertise in the company’s field of business, research, and product development. Antti has also demonstrated his commitment to the company and its development over the past few years. We thank Frans Wuite for his contribution as interim CEO of Herantis and wish Antti all the best in his new future role," says Timo Veromaa, Chairman of the Board of Herantis.

"It has been an honour to be closely involved in the development of Herantis and the company’s strategy over the last few years and to participate in the important work Herantis is doing in developing disease modifying therapies for Parkinson’s Disease. In my new role, I am able to utilize my knowledge of Herantis’ industry, business and strategic development, and I am excited about the opportunity to participate in Herantis’ next phases in a new role as CEO. I thank the Board of Directors of Herantis for the trust it has shown," says Antti Vuolanto.